Advertisement
Advertisement
MRKR
Marker Therapeutics, Inc. Common Stock
1.34
USDSponsored
+0.06
+4.76%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
1.35
+0.01
+0.75%
MRKR Earnings Reports
Positive Surprise Ratio
MRKR beat 19 of 27 last estimates.
70%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$695.64K
/-$0.18
Implied change from Q4 25 (Revenue/ EPS)
-36.99%
/+100.00%
Implied change from Q1 25 (Revenue/ EPS)
+99.32%
/-50.00%
Marker Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 18, 2026, MRKR reported earnings of -0.09 USD per share (EPS) for Q4 25, beating the estimate of -0.20 USD, resulting in a 55.13% surprise. Revenue reached 1.10 million, compared to an expected 695.64 thousand, with a 58.70% difference. The market reacted with a -1.49% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 695.64 thousand USD, implying an increase of 100.00% EPS, and decrease of -36.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Marker Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.09, beating estimates by 55.13%, and revenue of $1.10M, 58.7% above expectations.
How did the market react to Marker Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -1.49%, changed from $1.34 before the earnings release to $1.32 the day after.
When is Marker Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Marker Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $695.64K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement